John D. Mendlein, Ph.D.
Dr. Mendlein currently serves as CEO and executive chairman of aTyr Therapeutics and chairman for Fate Therapeutics. He served as CEO of Adnexus Therapeutics until Bristol-Myers Squibb (BMY) purchased the company after the award-winning partnership between Adnexus and BMY. Previously, Dr. Mendlein served as chairman and CEO at Affinium Pharmaceuticals, and he held a variety of roles, including board member, general counsel and chief knowledge officer, at Aurora Biosciences (acquired by Vertex Pharmaceuticals, VRTX). He has worked as an attorney at Cooley LLP, a law firm, in its life sciences and technology litigation practice groups and as a scientist in the Department of Molecular Biology and Protein Expression at Smith Kline & French, now GlaxoSmithKline. He is currently an advisory board member of Genesys Capital, a founder and board member of Homes for Sudan, a non-profit in Boston, and a scientific advisory board member for Ocean Discovery Institute, a non-profit in San Diego. He is the author or inventor of more than 30 publications and patents. Dr. Mendlein earned a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of Law and a B.S. in biology from the University of Miami.